Recent Advances in Pulmonary Inhalation of Nanoformulations

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: 31 March 2025 | Viewed by 4939

Special Issue Editors


E-Mail Website
Guest Editor
College of Pharmacy, Jinan University, Guangzhou 510632, China
Interests: inhalable nanomedicines; drug delivery; ferroptosis; protein corona; biological fate
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Lingang Laboratory, Shanghai, China
Interests: nano drug delivery system; biomimetic drug delivery system; lung cancer therapy

E-Mail Website
Guest Editor
School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China
Interests: cell therapy; bioinspired and biomimetic design; inhalable biomaterials

E-Mail Website
Guest Editor
School of Pharmaceutical Sciences, Capital Medical University, Beijing 100054, China
Interests: transdermal drug delivery system; inhalable nanoformulation; nanoparticles; microneedles; therapeutic mechanism

Special Issue Information

Dear Colleagues,

With the long-term development of nanoscience and nanotechnology, nanoformulations (to name a few, liposomes, solid lipid nanoparticles, polymeric micelles, metal-organic frameworks, exosomes, biomimetic nanoparticles, etc.) of versatile functions have widely been considered as promising therapeutics for various diseases. Since the new millennium, respiratory system diseases with growing mortality and morbidity impose severe burden on the patients and the society. They include: (1) Obstructive diseases, like asthma and chronic obstructive pulmonary disease (COPD); (2) Fibrotic diseases, like cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF); (3) Infectious diseases, like severe acute respiratory syndrome (SARS) and corona virus disease 2019 (COVID-19); (4) Neoplastic diseases, like small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Triggered by the clinical demand and aiming to manage and combat respiratory system diseases, the scientific community exploits the feasibility of using nanoformulations as innovative therapeutics. As the major lesion sites of these diseases locate in the respiratory system, pulmonary inhalation that can achieve a high accumulation in the respiratory tract will be a potent delivery route for the nanoformulations. Based on this rationale, a series of inhalable nanoformulations have been developed. We believe that through comprehensive investigation, the clinical translation of relevant systems can be anticipated, which ultimately alleviates the medical burdens of respiratory system diseases. The aim of this Special Issue is to highlight new developments in the field of pulmonary inhalation of nanoformulations intended for respiratory system disease treatment. All kinds of nanoformulations suitable for pulmonary delivery can be involved, e.g., liposomes, solid lipid nanoparticles, polymeric micelles, metal-organic frameworks, exosomes and biomimetic nanoparticles. The cargoes for these nanoformulations can be both small and large molecules. It is imagined that they are administrated to obstructive, fibrotic, infectious or neoplastic disease models. We would like to invite high-quality original researches and review papers dealing with abovementioned aspects. We particularly welcome those contributions with industrialization or translation focuses.

Dr. Zhengwei Huang
Dr. Tianqun Lang
Prof. Dr. Ling Guo
Dr. Yixuan Wang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pulmonary delivery
  • nanomedicines for inhalation
  • inhalable nanovaccines
  • nanoformulation design
  • respiratory system disease therapeutics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

16 pages, 346 KiB  
Review
Challenges and Opportunities in COPD Management in Latin America: A Review of Inhalation Therapies and Advanced Drug Delivery Systems
by Juan S. Izquierdo-Condoy, Camila Salazar-Santoliva, Daniel Salazar-Duque, Yorlenis-Del-Carmen Palacio-Dávila, Juan M. Hernández-Londoño, Rafael Orozco-Gonzalez, María-Silvana Rodríguez-Sánchez, Valentina Marín-Bedoya and Valentina Loaiza-Guevara
Pharmaceutics 2024, 16(10), 1318; https://doi.org/10.3390/pharmaceutics16101318 - 11 Oct 2024
Viewed by 738
Abstract
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, particularly in low- and middle-income countries, where it poses a significant burden. In Latin America, the estimated prevalence of COPD is notably high, but the management and treatment of [...] Read more.
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, particularly in low- and middle-income countries, where it poses a significant burden. In Latin America, the estimated prevalence of COPD is notably high, but the management and treatment of the disease have progressed slowly. This review examines the current status of inhalation therapy for COPD in Latin America, focusing on pharmacological therapies, inhalation devices, and the potential of advanced drug delivery systems. Pharmacological management predominantly relies on inhaled bronchodilators and corticosteroids, though access to these therapies varies considerably across the region. Inhalation devices, such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs), play a critical role in effective treatment delivery. However, their usage is often compromised by incorrect technique, low adherence, and limited availability, especially for DPIs. Emerging technologies, including nanoformulations, represent a promising frontier for the treatment of COPD by improving drug delivery and reducing side effects. However, significant barriers, such as high development costs and inadequate infrastructure, hinder their widespread adoption in the region. This review highlights the need for a multifaceted approach to enhance COPD management in Latin America, including optimizing access to existing inhalation therapies, strengthening healthcare infrastructure, improving provider training, and engaging patients in treatment decisions. Overcoming these challenges is crucial to improving COPD outcomes across the region. Full article
(This article belongs to the Special Issue Recent Advances in Pulmonary Inhalation of Nanoformulations)
22 pages, 2187 KiB  
Review
Nano-Formulations for Pulmonary Delivery: Past, Present, and Future Perspectives
by Siyuan Peng, Wenhao Wang, Rui Zhang, Chuanbin Wu, Xin Pan and Zhengwei Huang
Pharmaceutics 2024, 16(2), 161; https://doi.org/10.3390/pharmaceutics16020161 - 24 Jan 2024
Cited by 9 | Viewed by 3378
Abstract
With the development of nanotechnology and confronting the problems of traditional pharmaceutical formulations in treating lung diseases, inhalable nano-formulations have attracted interest. Inhalable nano-formulations for treating lung diseases allow for precise pulmonary drug delivery, overcoming physiological barriers, improving aerosol lung deposition rates, and [...] Read more.
With the development of nanotechnology and confronting the problems of traditional pharmaceutical formulations in treating lung diseases, inhalable nano-formulations have attracted interest. Inhalable nano-formulations for treating lung diseases allow for precise pulmonary drug delivery, overcoming physiological barriers, improving aerosol lung deposition rates, and increasing drug bioavailability. They are expected to solve the difficulties faced in treating lung diseases. However, limited success has been recorded in the industrialization translation of inhalable nano-formulations. Only one relevant product has been approved by the FDA to date, suggesting that there are still many issues to be resolved in the clinical application of inhalable nano-formulations. These systems are characterized by a dependence on inhalation devices, while the adaptability of device formulation is still inconclusive, which is the most important issue impeding translational research. In this review, we categorized various inhalable nano-formulations, summarized the advantages of inhalable nano-formulations over conventional inhalation formulations, and listed the inhalable nano-formulations undergoing clinical studies. We focused on the influence of inhalation devices on nano-formulations and analyzed their adaptability. After extensive analysis of the drug delivery mechanisms, technical processes, and limitations of different inhalation devices, we concluded that vibrating mesh nebulizers might be most suitable for delivering inhalable nano-formulations, and related examples were introduced to validate our view. Finally, we presented the challenges and outlook for future development. We anticipate providing an informative reference for the field. Full article
(This article belongs to the Special Issue Recent Advances in Pulmonary Inhalation of Nanoformulations)
Show Figures

Figure 1

Back to TopTop